Location History:
- London, GB (2004)
- Oxon, GB (2004 - 2007)
Company Filing History:
Years Active: 2004-2007
Title: Mark Uden - Innovator in Retroviral Vector Technology
Introduction
Mark Uden is a notable inventor based in Oxon, Great Britain, recognized for his contributions to the field of biotechnology. With three patents to his name, Uden has made significant strides in the development of retroviral vectors, which play a crucial role in genetic engineering and therapeutic applications.
Latest Patents
Among Uden's most recent innovations is his patent for retroviral vectors comprising a functional splice donor site and a functional splice acceptor site. This invention describes a retroviral vector that includes a functional splice donor site and a functional splice acceptor site, which flank a first nucleotide sequence of interest (NOI). The functional splice donor site is positioned upstream of the functional splice acceptor site, and the vector is derived from a retroviral pro-vector. Additionally, the pro-vector includes a first nucleotide sequence (NS) capable of yielding the splice donor site and a second NS for the splice acceptor site. The configuration of these elements allows for the formation of the retroviral vector through the reverse transcription process of the retroviral pro-vector.
Career Highlights
Mark Uden has significantly impacted the biotechnology industry through his work at various esteemed companies. Notably, he has been affiliated with Oxford Biomedica Limited and Oxford Biomedica, Inc., where he has contributed to pioneering research and development endeavors.
Collaborations
Throughout his career, Uden has collaborated with esteemed colleagues, including Christopher Robert Bebbington and Susan Mary Kingsman. These partnerships have played a vital role in driving innovation and expanding the horizons of retroviral vector technology.
Conclusion
Mark Uden's work in retroviral vector technology underscores his importance as an inventor in the biotechnology field. His patents reflect a commitment to advancing genetic research and developing innovative solutions that could benefit therapeutic applications. As he continues to further his work, the impact of his innovations is likely to be felt across various sectors of healthcare and scientific research.